NeuroPhage Pharmaceuticals Obtains $9,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
    NeuroPhage Pharmaceuticals
  • Mailing Address
    222 3rd St. Cambridge, MA 02142
  • Company Description
    NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company will use the financing to further the clinical development of NPT002.
  • M&A Terms
  • Venture Investor
    Shire Pharmaceuticals
  • Venture Investor

Trending on Xconomy